mRNA Expression and Genetic Polymorphisms Affecting DRD3 (rs6280) and HTR2A (rs6313) in Bruxism

ConditionBruxism

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-60

SponsorUniversity of Monastir

About this trial

The goal of this observational study is to learn about the genetic factors influencing bruxism, a condition characterized by teeth grinding, in a group of participants. The main questions it aims to answer are:

* Is there a significant association between the rs6313 polymorphism of the HTR2A gene and bruxism? * Is there a significant association between the rs6280 polymorphism of the DRD3 gene and bruxism?

Participants will:

Provide DNA samples for genotyping of the DRD3 (rs6280) and HTR2A (rs6313) polymorphisms.

Provide RNA samples to assess changes in the expression of HTR2A and DRD3. Researchers will compare the genetic data and RNA expression levels between individuals with bruxism and those without (controls) to see if there are significant genetic differences and expression changes associated with bruxism.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

be above 18 years of age and have a confirmed diagnosis of bruxism

Disqualifiers

Systemic diseases,

orofacial dysfunction,

acute symptoms such as neurodegenerative diseases (specifically Parkinsons disease),

Taking medication such as anxiolytics

Trial population

A total of 170 participants will be included in this study.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Genetic polymorphism
Genetic
The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

PCR-RFLP Analysis

Time frame

1 year

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Monastir

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: